Science Translational Medicine

Science Translational Medicine

Integrating Medicine and Science

1st Issue Published 7 October 2009

Mission statement | Purpose | Editors | Audience | Scope | Translational Medicine Defined | Content | Issue Elements | Translational Medicine Editorials | Press Releases and Announcements | Call for Papers | Information for Contributors | Subscription | Title Abbreviation | Advertising | Key Preliminary Dates | Download Poster | Contact Information

This video describes Science Translational Medicine, the newest journal from Science. The video features interviews with Katrina Kelner, Editor; Elias Zerhouni, Chief Scientific Adviser; Bruce Alberts, Editor-in-Chief of Science; and Alan Leshner, AAAS CEO and Executive Publisher, Science.

This item requires the Flash plug-in (version 8 or higher). JavaScript must also be enabled in your browser.

Please download the latest version of the free Flash plug-in.

Mission statement: To promote human health by providing a forum for communication and cross-fertilization among basic, translational, and clinical research practitioners and trainees from all relevant established and emerging disciplines.

Purpose: A profound transition is required for the science of translational medicine. Despite 50 years of advances in our fundamental understanding of human biology and the emergence of powerful new technologies, the rapid transformation of this knowledge into effective health measures continues to elude biomedical scientists. This paradox illustrates the daunting complexity of the challenges faced by translational researchers as they apply the basic discoveries and experimental approaches of modern science to the alleviation of human disease. Studies in humans often highlight deep gaps in our fundamental understanding of biology, but the linkages back to basic research to fill these gaps have not been as effective as they could be. Clearly, creative experimental approaches, novel technologies and new ways of conducting scientific explorations at the interface of established and emerging disciplines are now required to an unprecedented degree if real progress is to be made. Nothing short of a true reinvention of the science of translational medicine is likely to suffice. To aid in this reinvention, Science and AAAS have created a new interdisciplinary journal, Science Translational Medicine.


Chief Scientific Adviser
Elias A. Zerhouni, M.D.
Senior Fellow, Global Health Program, Bill & Melinda Gates Foundation
Former Director, National Institutes of Health

Katrina L. Kelner, Ph.D.
American Association for the Advancement of Science

Senior Editor
Kelly LaMarco, Ph.D.
American Association for the Advancement of Science

For a complete list of Advisory Board Members please click here [PDF].

Audience: Researchers and management in academia, government, and the biotechnology and pharmaceutical industries; physician scientists; regulators; policy makers; investors; business developers; and funding agencies.

Scope: Cancer, cardiovascular disease, metabolism/diabetes/obesity, neuroscience/neurology/psychiatry, immunology/vaccines, infectious diseases, policy, behavior, bioengineering, physics, chemical genomics/drug discovery, imaging, applied physical sciences, medical nanotechnology, drug delivery, biomarkers, gene therapy/regenerative medicine, toxicology and pharmacokinetics, data mining, cell culture, animal and human studies, medical informatics, other interdisciplinary approaches to medicine.

Translational medicine defined: Often described as an effort to carry scientific knowledge "from bench to bedside," translational medicine builds on basic research advances - studies of biological processes using cell cultures, for example, or animal models - and uses them to develop new therapies or medical procedures. Click here for more details.

Content: The editors and an international advisory group of clinician scientists and other experts will hold these articles to the same high-quality standard that is the hallmark of the journal Science.

  • Original, peer-reviewed, science-based research that successfully advances clinical medicine toward the goal of improving patients' lives
  • Research and commentary on models of human disease with significant implications for disease treatment
  • Investigative studies of human biology with an emphasis on disease, including small clinical trials
  • Perspectives and reviews on research topics that discuss the implications of the findings from a basic science and clinical point of view
  • Survey of recent significant findings from other publications
  • Commentary on policy, funding, and regulatory issues
  • Plus special issues to feature comprehensive reviews, and analyses of current topics in translational medicine

Future content: Meeting Reports, Teaching Resources

Issue elements: Approximately 1,500 print pages per year, 12 to 15 original peer-reviewed research papers per month/three to four per week

Translational medicine editorials:

"Drugs, Industry, and Academia," Science, June 20, 2008: Garrett A. FitzGerald, Director of the Institute for Translational Medicine and Therapeutics at the University of Pennsylvania, cites initiatives such as the Medicines for Malaria Venture and the TB Alliance as he examines issues faced by government and industry as translational medicine moves into the debate of treating disease and finding cures.

"Translational medicine: science or wishful thinking?" Journal of Translational Medicine, June 17, 2008: Martin Wehling describes "Translational medicine" as a fashionable term that is being increasingly used to describe the wish of biomedical researchers to ultimately help patients. It is therefore claimed that a new science needs to be developed called "translational science in medicine."

© 2008 Wehling; licensee BioMed Central Ltd.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Press releases and announcements: Elias Zerhouni, M.D., former Director of the National Institutes of Health, has been named Chief Scientific Adviser of Science Translational Medicine.

Call for papers: The editors are now accepting submissions for review. Click here for the editor's call for papers.

Information for contributors: Please review these instructions and information before submitting your manuscripts.


  • Online edition
    Published weekly, every Wednesday; 51 issues per year
    Subscription includes archive access
    ISSN: 1946 - 6242
  • Print edition
    Published monthly; 12 issues per year
    A compilation of a selection from weekly online editions
    ISSN: 1946 - 6234

Three-Year Institutional Sitewide Subscription Pricing and Agreement
The publisher of Science Translational Medicine, AAAS/Science, understands the challenges that many libraries are facing in this current economic climate. In recognition of those challenges and in order to help offset tightening budgets, AAAS/Science is pleased to offer a significant discount for those customers who subscribe to the new e-resource, Science Translational Medicine, before December 18, 2009. For orders placed before December 18, 2009, the price of a 2010 sitewide subscription will be reduced significantly off the list price. Furthermore, if you commit now for three years, AAAS will also substantially discount your second and third subscription years, 2011 and 2012. Please ask your representative for details or e-mail sciencemedicine{at}

Terms and Agreement
Science Translational Medicine
Three-Year Institutional Sitewide Subscription Agreement
Year-1: 2010
Year-2: 2011
Year-3: 2012

To qualify for this special three-year offer Licensee must:

  1. Elect to participate in the offer by confirming and accepting the 2010 Science Translational Medicine price quote via e-mail or in writing. This offer is valid until September 30, 2010.
  2. Pay in full the subscription fee for the initial term, Year-1, within 60 days of the invoice issue date.
  3. Have, at each renewal period during the three-year offer, an active Science Translational Medicine site license subscription in good standing that is fully paid for the prior period/term.
  4. Subscribe during 2010, 2011, and 2012 without cancellation.

Participation in this special offer program does not require advance payment for Year-2 or Year-3 of the three-year offer. Payment is due for Year-1, within 60 days of issuance of an invoice, and the same for each subsequent year at each renewal date.

Title abbreviation: Sci. Transl. Med.

Advertising: Digital, classified, and display advertising and sponsorships will be accepted.

Key preliminary dates:

  • Manuscript submission begins April 1, 2009.
  • Journal design finalized in April 2009.
  • Editorial board member nominations accepted through May 2009.
  • First editorial board meeting, May 6, 2009
  • First online issue posted October 7, 2009.
  • First sitewide trial period October-December 2009.
  • First print issue mailed October/November 2009.

Download poster

Please click here to download the baby genius Science Translational Medicine poster.

Contact information:

Sitewide subscriptions
1-866-265-4152 (toll-free in the USA)
+1-202-326-6730 (outside the USA)
Individual subscriptions